Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.70031 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Linong Ji und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Sitagliptin Phosphate, East Asian People. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk Shanghai (Ltd).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
This post hoc analysis investigates the impact of baseline characteristics on the efficacy and safety of oral semaglutide in a Chinese population with type 2 diabetes. Materials and Methods Chinese participants from the PIONEER 11 and 12 trials with type 2 diabetes aged ≥18 years were randomised to once‐daily oral semaglutide 3, 7, or 14 mg, or placebo (PIONEER 11) or sitagliptin 100 mg (PIONEER 12). Changes from baseline in HbA 1c and body weight at week 26 were analysed in subgroups according to the following baseline characteristics: age, HbA 1c , body mass index, duration of diabetes, and presence of gastrointestinal disease. Adverse events (AEs) by baseline subgroups were also assessed.
Results
In total, 390 (PIONEER 11) and 1084 (PIONEER 12) Chinese participants with type 2 diabetes were evaluated. Most baseline characteristics were similar across the two trials in the different subgroups. Overall, greater reductions in HbA 1c and body weight were observed with oral semaglutide versus comparators across the subgroups. A significant difference was observed for change in HbA 1c by baseline HbA 1c subgroups ( p int
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
- Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
- Department of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
- Novo Nordisk (Shanghai) Pharma Trading Co., Ltd, Beijing, China.
ORCID-Profile: Linong Ji, Guoyue Yuan
Förderung
- Novo Nordisk Shanghai (Ltd)
Zitieren
APA
Ji, L., Yuan, G., Liu, J., Zhang, B., Liu, W., & Shen, Z. (2025). Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70031
Vancouver
Ji L, Yuan G, Liu J, Zhang B, Liu W, Shen Z. Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70031
BibTeX
@article{Ji2025,
author = {Ji, Linong and Yuan, Guoyue and Liu, Jun and Zhang, Bingjie and Liu, Wenyan and Shen, Zewei},
title = {Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.70031}
}
EUVIMED